Half of people with HIV can start treatment on same day
Rapid treatment start doesn't benefit all
Same-day initiation of ART feasible and safe without CD4 counts, Thai study shows
Dolutegravir dual therapy works well for both first line and maintenance treatment
ADVANCE trial shows dolutegravir is highly effective in South Africa
Dolutegravir leads to weight gain in two African studies
Starting ART at a high CD4 cell count has clear benefits for people with a low viral load
Immediate treatment is probably especially beneficial for people with recent HIV infection
What works against self-stigma? First systematic review aims to find out
